Navigation Links
BlueInGreen® Demonstrates Better Water Treatment Solutions
Date:8/6/2013

Fayetteville, Arkansas (PRWEB) August 06, 2013

BlueInGreen, LLC recently completed a full scale demonstration of its proprietary CDOX® technology at a 120 million gallon per day (MGD) drinking water facility in the Midwest and is currently demonstrating at a municipal water treatment plant in another major city in the Midwest. The CDOX system dissolves carbon dioxide (CO2) gas into a small quantity of the treatment plant’s water and then disperses the dissolved CO2 solution into the rest of the water for the purpose of precise pH adjustment and stabilization of municipal/industrial water and wastewater. Controlling the water’s pH is necessary in order to ensure desired chemical reactions occur to remove contaminants from the water.

Due to new regulations concerning disinfection by-products, an increasing number of facilities are adding processes that utilize CO2 for pH adjustment. In addition, many treatment facilities are concerned for the safety of their employees due to the use of mineral acids, such as sulfuric, and are looking for a safer alternative. Others are looking for ways to improve efficiency and control over their existing pH adjustment processes to save money and improve water quality.

Such is the case at the 120 MGD facility mentioned, where recarbonation has historically been achieved using CO2 gas delivered via fine bubble diffusers. BlueInGreen’s CDOX system provided tighter control over pH and reduced total CO2 usage by 40% on average while using process water as the side-stream source and utilizing flow rates five times less than other systems on the market. This operations cost savings translates to a 3 year return on investment.

The company’s patented CDOX technology is unique in the industry, in that it is highly efficient, delivering nearly 100% utilization of vaporized gas. Recent installations have shown that BlueInGreen’s CDOX process makes it possible to deliver large quantities of gas in very small quantities of water – as much as 10 times less than the competition. This smaller carrier stream translates to reduced pumping costs as well as lower capital costs since smaller diameter piping, valves, flow meters, and other required components can be used.

Whether compared with conventional gas injection diffusers or other dissolved CO2 injection systems, the CDOX stands out with accurate pH control and reduced costs.

BlueInGreen, LLC is an environmental technology company established in 2004 to develop and sell high-efficiency, dissolved gas delivery technologies for use in wastewater, drinking water, and aquatic ecosystem restoration. The Company’s high-efficiency dissolved gas delivery systems include SDOX® (Super Saturated Dissolved Oxygen) for enhancing biological treatment processes, SDOX®-CS for odor and corrosion control of gravity sewers and force mains, HyDOZ® (Hyper-concentrated Dissolved Ozone) for disinfection, and CDOX® (Carbon Dioxide) for pH adjustment, water stabilization, and remineralization. BlueInGreen is actively addressing the global clean water supply and quality crisis by providing innovative products for improving water quality at lower cost and higher efficiency. BlueInGreen® is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11000755.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections
2. Marrone Bio Innovations’ Zequanox® Demonstrates Control of Zebra Mussels in Illinois Lake
3. NRL demonstrates high durability of nanotube transistors to the harsh space environment
4. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
5. Hark! Group demonstrates first heralded single photon source made from silicon
6. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
7. Nitor Group Demonstrates Direct Product Suite at Direct Implementation and Adoption Summit May 31-June 1
8. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
9. Entinostat Demonstrates Activity in Hodgkins Lymphoma
10. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
11. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... 5.0 of its award-winning CERF ELN (Electronic Laboratory Notebook) and ... knowledge asset manager used by laboratories, regulated scientific companies and biomedical organizations. ...
(Date:1/24/2017)... -- Neogen Corporation (NASDAQ: NEOG ) announced today ... (NASDAQ: SNES ) related to the manufacturing ... The two firms had worked together since 2014 — ... approved by the U.S. Environmental Protection Agency. ... only be used by a Licensed Pesticide Applicator. Further, the ...
(Date:1/24/2017)... January 24, 2017 According to a new market ... Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, ... by MarketsandMarkets, the global market is expected to reach USD 71.03 Billion ... 12.4% from 2016 to 2021. Continue Reading ... ...
(Date:1/24/2017)... , Jan. 24, 2017   Bracket , ... today announced the addition of Jennifer Peters ... Vice President and General Manager for the Scientific Services ... for Bracket,s work in Rater Training, Quality Assurance, and ... with a strong skillset and demonstrated record building technology-based ...
Breaking Biology Technology:
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
(Date:1/12/2017)... January 12, 2017 A new report by Allied Market Research, ... global biometric technology market is expected to generate revenue of $10.72 billion by 2022, ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):